Home › NDC Lookup › Ingredients › Olmesartan Medoxomil And Hydrochlorothia... › 65862-0779-30
⚪image loading
(from DailyMed)

Olmesartan Medoxomil and Hydrochlorothiazide 20 mg; 12.5 mg Tablet, Film Coated, 30-count — NDC 65862-779-30 (Billing 65862-0779-30)

by Aurobindo Pharma Limited · 30 TABLET, FILM COATED in 1 BOTTLE

This is a package of 30 tablets of Olmesartan Medoxomil and Hydrochlorothiazide 20 mg; 12.5 mg Tablet, Film Coated from Aurobindo Pharma Limited, marketed since Apr 2017 and currently FDA-listed; retail pharmacies pay about $0.1650 per tablet (NADAC).

NDC 65862-0779-30
🏷️ FDA NDC (as labeled) 65862-779-30 billing pads the product segment with a zero
This package
Contains30-count Cost per ea$0.1650 NADAC Per package$4.95 / 30 tablets Pack sizes5 compare ↓
Also priced by: Medicaid pays $0.3765/unit · Part D plans $0.3606/unit — full pricing hub ↓
Product page 65862-0779-90 Also comes in: 10 tablets 65862-779-78 90 tablets 65862-779-90 1000 tablets 65862-779-99 4000 tablets 65862-779-49
On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 65862-779-30 alone.

Record
FDA NDC Directory package listing · Drug for further processing
Code segments
65862 labeler · 779 product · 30 package
Listing certified through
Dec 31, 2026
Billing quantity
30 EA per package
Barcode (UPC-A, from the NDC)
3 6586277930 4
Medicaid fills, this package
3,527 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 65862-779-30
Product NDC 65862-779
11-digit billing NDC 65862077930
NCPDP billing unit EA — each (per item)
SPL Set ID b7b662be-f0c8-4ada-9862-9e59d3b4aea5
DEA schedule Non-controlled
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2017-04-24
Dosage form TABLET, FILM COATED
Substance OLMESARTAN MEDOXOMIL; HYDROCHLOROTHIAZIDE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 36994002500320
GPI class Olmesartan Medoxomil-HCTZ
GCN Seq No 052833
GCN 20074
HICL code 025446
Ingredient (HICL) Olmesartan/Hydrochlorothiazide
HIC1 code A
Therapeutic class — broad (HIC1) Cardiovascular System
HIC2 code A4
Therapeutic class — intermediate (HIC2) Antihypertensives
HIC3 code A4I
Therapeutic class — specific (HIC3) Angiotensin Receptor Antag.-Thiazide Diuretic Comb
AHFS code 24:32.08.00
AHFS class Angiotensin Ii Receptor Antagonists
FDB label name OLMESARTAN-HCTZ 20-12.5 MG TAB
FDB brand name Olmesartan-Hydrochlorothiazide
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 052833
  • GCN: 20074
  • GPI-14 (Medi-Span): 36994002500320
  • HICL (First Databank): 025446
  • AHFS class code: 24:32.08.00
Why two NDCs? The FDA registers this code as 65862-779-30 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 65862-0779-30. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name OLMESARTAN-HCTZ 20-12.5 MG TAB Ingredient Olmesartan/Hydrochlorothiazide
📖 About the active ingredient: Olmesartan Medoxomil; Hydrochlorothiazide MedlinePlus · NLM
General information about the ingredient itself — the description of this specific product follows below.

Hydrochlorothiazide is used alone or in combination with other medications to treat high blood pressure. Hydrochlorothiazide is used to treat edema (fluid retention; excess fluid held in body tissues) caused by various medical problems, including heart, kidney, and liver disease and to treat edema caused by using certain medications including estrogen and corticosteroids. Hydrochlorothiazide is in a class of medications called diuretics ('water pills'). It works by causing the kidneys to get rid of unneeded water and salt from the body into the urine. High blood pressure is a common condition...

Read the full MedlinePlus article ↗
🧪 What is this product?

This is a prescription film-coated tablet taken by mouth that contains olmesartan medoxomil and hydrochlorothiazide. Olmesartan medoxomil is an angiotensin II receptor blocker, and hydrochlorothiazide is a thiazide diuretic. These two ingredients are typically used together to help manage high blood pressure by working through different mechanisms to relax blood vessels and reduce fluid in the body.

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.165 $4.95 / 30 tablets
Medicaid paysCMS SDUD · 12 mo $0.3765 $11.30 / 30 tablets
Medicare drug plans payPart D · Q2 2026 $0.3606 $10.82 / 30 tablets
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.241 $0.165
▼ Down 30% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
65862-0779-30 You're viewing this 30 TABLET, FILM COATED in 1 BOTTLE $0.1650 / ea $4.95 2017-04-24 — Active
65862-0779-78 65862-779-78 10 BLISTER PACK in 1 CARTON / 10 TABLET, FILM COATED in 1 BLISTER PACK — — 2017-04-24 — Active
65862-0779-90 65862-779-90 Main listing 90 TABLET, FILM COATED in 1 BOTTLE $0.1650 / ea $14.85 2017-04-24 — Active
65862-0779-99 65862-779-99 1000 TABLET, FILM COATED in 1 BOTTLE — — 2017-04-24 — Active
65862-0779-49 65862-779-49 4000 TABLET, FILM COATED in 1 BAG — — — — Active

This pack has the lowest per-ea cost of the 2 priced pack sizes ($0.1650 NADAC).

This pack accounts for about 43% of this product's recent Medicaid fills; most go to the 90 tablets pack. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 30-count package — 30 tablet, film coated in 1 bottle.
How does this package differ from NDC 65862-0779-90?
Both are Olmesartan Medoxomil and Hydrochlorothiazide 20 mg; 12.5 mg Tablet, Film Coated — the drug itself is identical. This page's package is the 30-count one, while NDC 65862-0779-90 is the 90 tablets package.
What NDC number is used to bill for this package of Olmesartan Medoxomil and Hydrochlorothiazide 20 mg; 12.5 mg Tablet, Film Coated?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Olmesartan medoxomil and hydrochlorothiazide 20 mg/1; 12.5 mg 31722-0886-30 Camber 30 tablets $0.165 AB Availability likely —
OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE 20 mg/1; 12.5 mg 33342-0173-07 Macleods 30 tablets $0.165 AB Availability likely —
OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE 20 mg/1; 12.5 mg 43547-0391-03 Solco 30 tablets $0.165 AB Availability likely —
Olmesartan Medoxomil and Hydrochlorothiazide 20 mg/1; 12.5 mgthis 65862-0779-30 Aurobindo 30 tablets $0.165 — Availability likely —
Olmesartan Medoxomil And Hydrochlorothiazide 20 mg/1; 12.5 mg 67877-0453-30 Ascend 30 tablets $0.165 AB Availability likely —
olmesartan medoxomil-hydrochlorothiazide 20 mg/1; 12.5 mg 72205-0147-30 Novadoz 30 tablets $0.165 AB Availability likely —
OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE 20 mg/1; 12.5 mg 72603-0290-01 NorthStar 30 tablets $0.165 AB Availability likely —
Olmesartan Medoxomil And Hydrochlorothiazide 20 mg/1; 12.5 mg 16729-0366-15 Accord 90 tablets $0.175 AB Availability likely +6%
Benicar HCT 20 mg/1; 12.5 mg 00713-0863-30 Cosette 30 tablets $11.317 AB Availability likely +6758%
Benicar HCT 20 mg/1; 12.5 mg 00713-0943-30 Cosette 30 tablets — AB FDA listed —
olmesartan medoxomil-hydrochlorothiazide 20 mg/1; 12.5 mg 42291-0924-90 AvKARE 90 tablets — AB FDA listed —
Olmesartan Medoxomil and Hydrochlorothiazide 20 mg/1; 12.5 mg 46708-0149-08 Alembic 80 tablets — AB FDA listed —
Olmesartan Medoxomil and Hydrochlorothiazide 20 mg/1; 12.5 mg 50090-3701-00 A-S 30 tablets — AB FDA listed —
OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE 20 mg/1; 12.5 mg 50090-6836-00 A-S 30 tablets — AB FDA listed —
OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE 20 mg/1; 12.5 mg 50090-7478-00 A-S 30 tablets — AB FDA listed —
OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE 20 mg/1; 12.5 mg 50228-0342-10 ScieGen 1000 tablets — AB FDA listed —
Olmesartan Medoxomil and Hydrochlorothiazide 20 mg/1; 12.5 mg 62332-0149-08 Alembic 80 tablets — AB FDA listed —
Olmesartan Medoxomil and Hydrochlorothiazide 20 mg/1; 12.5 mg 70756-0812-12 Lifestar 1000 tablets — AB FDA listed —
OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE 20 mg/1; 12.5 mg 71335-2424-01 Bryant 30 tablets — AB FDA listed —
OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE 20 mg/1; 12.5 mg 71335-3029-01 Bryant 30 tablets — AB FDA listed —
OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE 20 mg/1; 12.5 mg 84677-0056-10 Golden 1000 tablets — AB FDA listed —
Olmesartan Medoxomil and Hydrochlorothiazide 20 mg/1; 12.5 mg 60290-0102-01 Umedica 30 tablets — AB FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2017
On the market since
Apr 2017
📍
2026
Currently FDA-listed
9 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAurobindo Pharma Limited
Labeler code65862
First marketedApr 2017
Product typeDrug For Further Processing
Portfolio1,464 products on file

More NDCs from Aurobindo Pharma Limited labeler code 65862

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
3.5K
Units reimbursed last 4 qtrs
162.1K
Gross reimbursed last 4 qtrs
$61K
Avg / prescription
$17.30
Avg / unit
$0.3765
Latest quarter Q1 2026
651Rx
Medicaid pays / ea
$0.3765
gross reimbursed
vs
NADAC / ea
$0.1650
acquisition cost
=
Spread
+$0.2115
+128% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
42% FFS 58% MCO
Fee-for-service · 1,472 Rx Managed care · 2,055 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 720 units · 9.2 per 100k residents WA Idaho: 1,115 units · 56.8 per 100k residents ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: 2,525 units · 42.7 per 100k residents WI Michigan: 12,950 units · 129 per 100k residents MI New York: 29,069 units · 149 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 3,263 units · 77.1 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: 6,814 units · 57.8 per 100k residents OH Pennsylvania: 9,583 units · 73.9 per 100k residents PA New Jersey: 12,325 units · 133 per 100k residents NJ Massachusetts: 810 units · 11.6 per 100k residents MA California: 23,304 units · 59.8 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 3,510 units · 77.6 per 100k residents KY West Virginia: 1,055 units · 59.6 per 100k residents WV Virginia: 715 units · 8.2 per 100k residents VA Maryland: 540 units · 8.7 per 100k residents MD Connecticut: 5,442 units · 150 per 100k residents CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 6,945 units · 97.5 per 100k residents TN North Carolina: 17,707 units · 163 per 100k residents NC South Carolina: no data reported SC Delaware: 4,170 units · 404 per 100k residents DE Oklahoma: 810 units · 20.0 per 100k residents OK Louisiana: 11,184 units · 245 per 100k residents LA Mississippi: 3,570 units · 121 per 100k residents MS Alabama: no data reported AL Georgia: 1,830 units · 16.6 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 580 units · 1.9 per 100k residents TX Florida: 1,530 units · 6.8 per 100k residents FL
Units reimbursed · per 100k residents
1.9404
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Delaware 404 /100k
2 Louisiana 245 /100k
3 North Carolina 163 /100k
4 Connecticut 150 /100k
5 New York 149 /100k
6 New Jersey 133 /100k
7 Michigan 129 /100k
8 Mississippi 121 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
90 tablets65862-0779-90 4,693 Rx · $88,424
30 tablets this page65862-0779-30 3,527 Rx · $61,011
10 tablets65862-0779-78 No Medicaid data
1000 tablets65862-0779-99 No Medicaid data
4000 tablets65862-0779-49 No Medicaid data
Drug total (last 4 qtrs): 8,220 Rx · 418,347 units · $149,435 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

About this NDC listing & data coverage

Listed for further processing / repackaging

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Aurobindo Pharma Limited supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Aurobindo Pharma Limited. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 4 other package presentations of this same product, including 10 tablets (65862-0779-78), 90 tablets (65862-0779-90), 1000 tablets (65862-0779-99). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Aurobindo Pharma Limited is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 65862-0778-28 · Aurobindo 65862-0780-30 · Aurobindo →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.